Conavi Medical Corp. designs and manufactures imaging technologies for minimally invasive cardiovascular procedures. The company boasts a strong gross margin of 100%, indicating effective cost management; however, it faces significant challenges with negative EBITDA and net margins, suggesting operational inefficiencies. The current and quick ratios above 1 indicate adequate liquidity, but the high negative return on assets raises concerns about profitability. Overall, while Conavi has promising technology, its financial health reflects substantial operational hurdles that need addressing.
Loading financial metrics...
Company has $4.5M in cash but burned $5.9M last quarter. At this burn rate, only 0.8 quarters of runway remain without additional financing.
Company posted a loss of $-17.8M over the last year, representing 2294.2% of revenue.
Debt of $18.2M is 4.1x the company's cash position of $4.5M.
Operating cash flow has been negative for 3 consecutive quarters, burning $23.7M over the last year.
Exceptional revenue growth of 69.5% YoY demonstrates strong market demand and competitive positioning.
Gross margin expanded by 76.7 percentage points, indicating improved pricing power or cost efficiency.
Operating margin expanded by 617.9pp, demonstrating strong operational leverage.
Both gross margin (+76.7pp) and operating margin (+617.9pp) are expanding simultaneously, indicating the company is scaling profitably.
Exceptional gross margin of 95.6% indicates strong pricing power and competitive moat.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Medical Devices companies of a similar size
Based on 2026-Q2 (March 31, 2026)